Trial Profile

Effect of palivizumab on respiratory syncytial virus-associated burden of disease: a randomised controlled trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palivizumab (Primary)
Indications Respiratory syncytial virus infections; Wheezing
Focus Proof of concept; Therapeutic Use
Acronyms MAKI

Most Recent Events

01 Dec 2021 Results assessing the effects of early life RSV prophylaxis on having RSV infection and asthma symptoms in the first years of life and performed an EWAS to identify differentially methylated patterns in relation to palivizumab prevention at the global, individual, and regional CpG site level, published in the Pediatric Pulmonology.
09 May 2013 Status changed from recruiting to completed.
09 May 2013 Results published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com